Program

8th Asian Biologics and Biosimilars Congress


Expert Speakers. Evidence based. Health Care Professionals.

August 10-12, 2017 Beijing, China



Seating is Limited
Register Today!

Conference Secretariat
2360 Corporate Circle, Suite 400 Henderson
NV 89074-7722, USA
Conference Series
Direct: (702) 508-5200 Ext: 8083
Tel: +1 (800) 216 6499
Email: biosimilarsasia@pharmaceuticalconferences.org



Welcome Message

Dear Colleagues, Scientists and Friends,

The Organizing Committee is delighted to invite you to attend the 8th Asian Biosimilars Congress, one of its remarkable pharmaceutical conferences, to be held during August 10-12, 2017 in Beijing, China. The Asian Biosimilars Congress 2017 brings together scientists, researchers, industry and CRO representatives from around the world.

As of December 2016 there were 23 biosimilars marketed in the EU and 4 biosimilars licensed in the USA. As such, the biosimilars market is expected to experience an exponential growth over the coming few years. Many new biologics are making their entry in the pharma market and experiencing a notable rise in their usage compared with the conventional medications.

The 8th Asian Biosimilars Congress will present multiple aspects of biosimilars from the passage of biosimilars through a decade in Asia to the latest developments in the field of biologics and biosimilars. The whole range of portfolio selection, development, regulatory requirements and marketing will be presented.

You can join your peers from around the world focused on learning about biologics and biosimilars-related advances, which is your single best opportunity to reach the largest assembly of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with professionals, make a splash with new research, and receive name recognition at this 3-day event.

The congress will provide enough space for discussion, meetings and workshops in order to allow a close contact between speakers and visitors.

We are looking forward to see you in Beijing, China

Raymond Huml, MS, DVM, RAC, QuintilesIMS
Oxana Iliach, PhD, QuintilesIMS
Charu Manaktala, MD, QuintilesIMS



Welcome Message

Dear Industry Colleagues, Scientists and Friends,

As a member of the Organizing Committee I am delighted to invite you to attend the 8th Asian Biologics and Biosimilars Congress to be held from August 10-12, 2017 in Beijing, China. The Asian Biosimilars Congress 2017 brings together biopharmaceutical industry colleagues, scientists, researchers, regulatory, and clinical experts from around the globe to bring to you the cutting edge information for the development of biosimilars.

The 8th Asian Biologics and Biosimilars Congress is designed to bring forth the most up to date information for the development of biosimilars. Key aspects will include regulatory, CMC, clinical and marketing considerations, as they relate to what it will take to bring these lifesaving/life altering products to the highly regulated Western Markets.

Please join your peers from around the world for this wonderful opportunity to reach the largest assembly of participants from the Biologics/Biosimilars community, meet with thought leadership experts, share your new research, and show off your cutting edge technology at this 3-day event.

I look forward to seeing you in Beijing, China at the 8th Asian Biologics and Biosimilars Congress.

Kamali Chance

MPH, PhD, RAC

Vice President

Head, Global Biosimilars Regulatory Strategy

Biosimilars Center of Excellence

QuintilesIMS


Keynote Speakers @ Asian Biosimilars 2017
Kamali Chance
Vice President, Head, Global Biosimilars Regulatory Strategy
Quintiles, Inc.
USA
Raymond Huml
Vice Precident
Quintiles IMS
USA
Oxana Iliach
Sr. Director
Quintiles IMS
Canada
Jianguo Yang
President / CEO, Abpro
China Division
USA
Charu Manaktala
Senior Medical Director
Quintiles IMS
India
Hossein Pakdaman
President of Iranian Neurological Association
Iran


Special Session on
Asian Biosimilars 2017
Pfizer
Biosimilars: Challenges in Safety and Risk Management
Asif Mahmood
Disease Area Cluster Lead for Biosimilars Pfizer, USA



Confreence Highlights

- Latest Biosimilars in Asian Scenario
- Biosimilars- Hatch-Waxman Act & BPCI Act
- Challenges in Developing Biosimilars
- Biosimilars Research Pipeline
- Current Developments in The Field of Biosimilars
- Pharmacovigilance of Biosimilars
- Emerging Trends in Biosimilars
- Biosimilars Market- Challenges & Prospects
- Cost Analysis of Biosimilars
- Globalization of Biosimilars
- Biosimilars Analytical Strategies
- Emerging Biosimilars in Therapeutics
- Clinical Studies on Biosimilars
- BCS & IVIVC Based Biowaivers
- Entrepreneurs Investment Meet

** Speaker Slots are Available **


Organizing Committee Members



Kamali Chance
Vice President
Quintiles, Inc.
USA



Oxana Iliach
Sr. Director
Quintiles IMS
Canada



Raymond Huml
Vice Precident
Quintiles IMS
USA



Hossein Pakdaman
Shahid Beheshti University
of Medical Sciences
Tehran, Iran



Candida Fratazzi
President
BBCR Consulting
USA



Charu Manaktala
Senior Medical Director
Quintiles IMS
India



Asif Mahmood
Disease Area Cluster
Lead for Biosimilars Pfizer
USA



Suzette DiMascio
CEO & President
CSI Specialty Group
USA



T. Santha Raju
Sr. Director & Head
MedImmune
USA



Lutz Hilbrich
Head of Biosimilars
Platform in China Shanghai,
China



Osama O. Ibrahim
Consultant Biotechnology/
Food Safety
Bioinnovation, USA



Jianguo Yang
President / CEO Abpro
China Division
USA

8th Asian Biologics and Biosimilars Congress

August 10-12, 2017 Beijing, China

Top Participating Organisations



Tentative Program

Keynote Forums

Title: FDA/EMA Current Thinking on Totality of Evidence for Development of Biosimilars
Kamali Chance, Vice President, Head, Global Biosimilars Regulatory Strategy, Biosimilars Center of Excellence, Quintiles, Inc., USA
Title: Biosimilars: Accelerating Early Clinical Development
Raymond Huml, Vice Precident, Quintiles IMS, USA
Title: Strategy for the Global Development of Biosimilars: putting it's all together
Oxana Iliach, Sr. Director, Quintiles IMS , Canada
Title: Strategic Partnership for China Biologics
Jianguo Yang, President / CEO, Abpro China Division, USA
Title: Clinical Development of Biosimilars for Western Markets: Planning for Success
Charu Manaktala, Senior Medical Director, Quintiles IMS, India
Title: Biosimilars in treatment of multiple sclerosis in Iran
Hossein Pakdaman, President of Iranian Neurological Association, Iran

Special Sessions

Title: Biosimilars: Challenges in Safety and Risk Management
Asif Mahmood, Disease Area Cluster lead for Biosimilars, Pfizer, USA

Scientific Sessions

Title: Update on biosimilars litigation in the U.S.: What if you don't want to dance?
George C. Yu, J.D., M.S., Schiff Hardin LLP, USA
Title: Challenges in Assessing Therapeutic Equivalence of Nano-Similars
Beat Flühmann, Director Vifor Pharma Ltd, Switzerland
Title: Biosimilar Globalization- A silver lining in untested waters! Biosimilars in China: balance of risks and opportunities.
Candida Fratazzi MD, President, BBCR Consulting, USA
Title: The role of regulatory policies in relation to the local biosimilars production
Gustavo H. Marin, PhD, UNLP-CONICET, Argentina
Title: Practical Considerations in Clinical Strategy to Support the Development of Biologics Device Combination Products
Zhaoyang Li, Director, Sanofi, USA
Title: Expression of with Shiga like toxin (SLT) fused to vascular endothelial growth factor (VEGF) in E coli for targeting angiogenesis
Osama O. Ibrahim Ph.D.,Consultant Biotechnology, Bio Innovation LLC, USA
Title: Medicines distributions and financing alternatives
Abdeen M Omer, PhD, Khartoum, Sudan
Title: Some Considerations about Biosimlar Safety
Samer M. Al-Hulu, PhD, Al-Qasim Green University , Iraq
Title:The study of Antimicrobial and anti-Alzheimer's effects of turmeric extract based on amyloid nano-bio-fibrils formation inhibition method
Amir Arasteh, Assistant Professor of Biochemistry, Department of biology, Rasht Branch, Islamic Azad University, Rasht, Iran
Title: Evaluation The Cytotoxicity Of An Oscillatoria Sp. Extract On Breast Cancer Cell Line (Mcf-7) And Assessment Of Noxa Gene Expression
Ali Salehzadeh, Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran
Title: Significance of stability and temperature excursion studies for Biologistics
Rajiv Dua, Site ATS Head, Sun Pharmaceuticals Ltd, India
Title: Global Status of Biosimilars & Prospects in Asia
Md Abu Zafor Sadek, Institute of Business Administration, University of Dhaka, Bangladesh
Title: Bioassay-Directed Isolation Of Hypotensive Alkaloids From Holarrena Pubescens
Aftab Khalid, H.E.J. Research Institute of Chemistry, University of Karachi, Pakistan
Title: Heterogeneity of Monoclonal Antibody and Challenges in Developing Biosimilar of it
Sunit Maity, PhD, Zumutor, India

Speaker Slots Available

NOTE: Program is subject to change with final allotment of the speaker slots

Previous Speakers



Patrick Lucy
Pfenex Inc. , USA



Alex Brill
Matrix Global Advisors , USA




Jill A. Myers
Momenta Pharmaceuticals, USA



Jenny Chen
Wolf, Greenfield & Sacks, P.C , USA



Milind Antani
Nishith Desai Associates, India



William A. Sarraille
Sidley Austin LLP
USA



Timothy J Shea
Sterne, Kessler, Goldstein & Fox P.L.L.C , USA



Denise M Kettelberger
Sunstein Kann Murphy & Timbers LLP, USA



Gregory J Glover
Pharmaceutical Law Group PC, USA



Christopher J Leintz
Pfizer, Inc, USA



Subir Roy
DGM- Marketing & Medical at Zydus Cadila, India



Sunit Maity
Theramyt Novobiologics Pvt. Ltd., India




Mark A. Emalfarb
Dyadic International, Inc.
USA



Vivek Kumar Morya
Inha University, Republic of Korea.
South Korea




Abdel Halim Harrath
King Saud University
Saudi Arabia



Neil Schauer
Avaxia Biologics
USA

Previous Speakers




Sarfaraz K. Niazi
TheraProteins, USA



Angela Furlanetto
Dimock Stratton LLP
Canada



Ronald A Rader
Biotechnology
Information Institute, USA



Raymond A Huml
Quintiles, Inc., USA



James Harris III
Healthcare
Economics LLC, USA




Lisa Mueller
Michael Best &
Friedrich LLP, USA



Raj Dave
Pillsbury Winthrop Shaw
Pittman, LLP, USA



Kerisha A. Bowen
Dentons US LLC, USA



Abe Hershkovitz
Hershkovitz &
Associates, PLLC, USA



Nigel J Rulewski
Quintiles, Inc., USA



András Guttman
University of
Pannonia,Hungary SCIEX, USA



Sumant Chaubey
Bills Biotech, India



Andreu Soldevila
CEO LeanBioPro
Spain



Tom Carver
Wragge Lawrence
Graham & Co, UK



Christoph Volpers
Senior Patent Consultant
at Michalski &
Hüttermann, Germany



Wolfgang A. Rehmann
Taylor Wessing
Germany

Previous Speakers



Marcus Mreyen
Protagen Protein Services GmbH, Germany



Min Zhang
Fujifilm Diosynth Biotechnologies USA



Fiona M Greer
SGS Life Sciences Switzerland




Volker Schellenberger
Amunix Operating Inc. USA



Alan L. Epstein
USC Keck School of Medicine, USA



Upendra Nagaich
Amity Institute of Pharmacy, India



Gene M. Ransom, III
University of Maryland and University of Baltimore School of Law, USA



Gordon T. Bolger
Nucro-Technics Canada



Adetunji Olawale
Osun State Polytechnic Nigeria



Afshin Safavi
BioAgilytix, USA



Mariana Babayeva
Touro College Of Pharmacy USA



Andy Upsall
BioOutsource, UK



Samantha Little
Covance Laboratories Ltd, UK



Kamali Chance
Quintiles Inc., USA



Mario DiPaola
Blue Stream Laboratories, Inc., USA



Francesco Marchesi
Regina Elena National Cancer Institute, Italy

Previous Speakers



Candida Fratazzi
BBCR Consulting, USA



Krishna Menon
Cellceutix
Corporation, USA



Daniel Galbraith
BioOutsource Ltd, UK



Siddhartha Roy
CSIR - Indian Institute of
Chemical Biology, India



Noelle Sunstrom
Neuclone PTY LTD
Australia



Dipti Gulati
PJI Biotech, USA



Alexander Pitters
Kaiser Optical Systems
France



Laszlo Endrenyi
University of Toronto
Canada



Christina Vessely
Biologics Consulting, USA



Ruideger Janwosky
Cinfa Biotech GmbH
Germany



Christelle Dagoneau
Catalent Biologics
USA



Aparna Kasinath
Syngene International
India

Why to Attend???

Join your peers around the world focused on learning about Biologics and Biosimilars related advances, which is your single best opportunity to reach the largest assemblage of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 3-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

At Asian Biosimilars 2017 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community.

Abstract Information: Oral / Poster Presentation Guidelines

Oral Presentations are generally split into TWO categories, as follows:

1. Plenary Lectures
   - Each Plenary lecture is 25 minutes in length and comprises one presentation. We recommend you plan to present for approximately 20 minutes with 5 minutes for questions/discussion.
   - Where Plenary Lectures are presented as debates, each of two speakers should plan to present for 20 minutes, allowing five minutes for closing questions and conclusions. We recommend that invited speakers communicate in advance of the Moderator so that presentations may be coordinated.
2. Oral Sessions
   - Each Oral Session is 60 minutes in length and comprises two presentations, of 30 minutes each. We recommend that you plan to present for approximately 15 minutes, allowing time for questions/discussion at the end of the presentation.

Please prepare you presentation in 16:9 format (screen are in format 16:9). We recommend you to save your PowerPoint presentation using PPT(X) format instead of PPS.

A technician is available in every session room to provide assistance when needed. Due to the online presentation system, all speakers are kindly requested to use provided PC onsite. Please be present in the session room 15 minutes prior the start of your session and follow the instructions from the Chairs and/or technician. During your presentation a remote control will be available for controlling your presentation. Please observe the time allotted to you as you will not be permitted to speak for longer time. At the end of the Congress, all presentations will be deleted from the presentation system and computers on-site.

Speaker Preview Room

All speakers are asked to upload their presentation at the Speaker Preview Room (located in the Registration area) at least one hour before the beginning of the session or the day before in case of a morning session.

Poster Guidelines

The poster exhibition will be an integral part of Med Pharma Congress.

The poster exhibition will be located on the exhibition area of the congress centre. The area will be clearly signposted from the registration area.

Technical Instructions:

- Posters must be prepared in Portrait style.
- Please DO NOT prepare a landscape poster
- The dimensions should be 100 cm high by 70 cm wide
- Posters should be attached to the boards with stickers, which you will be supplied to the organizers.
- Poster session schedule Posters will be displayed and presented in session.

Please plan to be at your poster and available to answer questions from delegates at the time of your assigned poster session. Posters will be displayed according to the POSTER numbers given by the organizers and will be grouped by sub topic.

Young Researchers Forum

The Young Researchers Forum offers young researchers the possibility to meet and discuss research topics and methodologies, share and develop ideas, learn from each other and gain knowledge from senior researchers.

Young Researcher Sessions are organized at the Med Pharma Congress, to provide a unique platform for Young Researchers/Investigators for presenting latest research projects with an in-depth analysis. Young Investigators (e.g. Post-Graduate students, Post-doctoral fellows, Trainees, Junior faculty) are the focus of this event. Participants should be below the age of 33 years. All submissions must be in English.

The prize winning papers will be considered for publication in the international journals once the paper is subjected to standard review procedures.

For further information please contact: biosimilarsasia@pharmaceuticalconferences.org



Registration Information

How To Register

Website: http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

Registration Fees

- Early registration fee: $799
- (SAVE $100.00 — DEADLINE: May 25, 2017)
- Regular registration fee: $899
- SAVE $100.00 — February 28, 2017 through June 27, 2017)
- Late registration fee: $999
- Group Discount: Register three or more attendees and receive $50.00 off per person
- Student Registration: $249
- Young Researchers Forum Fee: 399$

Cancellation Policy

Cancellations must be received in writing 60 days prior to the meeting and are subject to a $100 processing fee. Refunds will not be granted after April 03, 2017, nor will they be given for no-shows. Please email cancellations to biosimilarsasia@pharmaceuticalconferences.org

Accommodations

Double Tree by Hilton Beijing
168 Guang An Men Wai Avenue Xi Cheng District,
Beijing 100055
China

To make reservations and ensure that you will have a hotel room at the same location as the conference, please choose your package and register at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

Payments

We accept Visa, Master Card, American Express and checks. If paying by credit card, please utilize our online registration site located at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

If you wish to pay by check, please contact biosimilarsasia@pharmaceuticalconferences.org

For more information:

Questions? Contact 1 (800) 216 6499 or inquiries: biosimilarsasia@pharmaceuticalconferences.org

Register now at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//

Stay Connected Before, During and After the Event!

Program

Day 1: August 10, 2017

Opening Ceremony

Conference Souvenir Launch
New Perspective frontiers in the area of Biologics and Biosimilars
Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
Group Photo

Speaker Forum

Sessions Chair's Introduction
Track 1: Latest Biosimilars in Asian Scenario
Track 2: Biosimilars- Hatch-Waxman Act & BPCI Act
Track 3: Challenges in Developing Biosimilars
Track 4: Biosimilars Research Pipeline
Track 5: Current Developments in The Field of Biosimilars
Panel discussions and Reviews

Lunch Break

Young Research Forum
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
B2B Meetings
Certificates Felicitation by the organizing Committee

Day 2: August 11, 2017

Introduction

Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments

Speaker Forum

Sessions Chair's Introduction
Track 6: Pharmacovigilance of Biosimilars
Track 7: Emerging Trends in Biosimilars
Track 8: Biosimilars Market- Challenges & Prospects
Track 9: Cost Analysis of Biosimilars
Track 10: Globalization of Biosimilars
Panel discussions and Reviews

Lunch Break

Young Research Forum
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
B2B Meetings
Certificates Felicitation by the organizing Committee

Day 3: August 12, 2017

Introduction

Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments

Speaker Forum

Sessions Chair's Introduction
Track 11: Biosimilars Analytical Strategies
Track 12: Emerging Biosimilars in Therapeutics
Track 13: Clinical Studies on Biosimilars
Track 14: BCS & IVIVC Based Biowaivers
Track 15: Entrepreneurs Investment Meet
Panel discussions and Reviews
Young Research Forum
(Panel discussions and Reviews)

Lunch break

Speaker Sessions (Cont...)
Poster Sessions Evaluation by the Committee
Refreshments
Award Ceremony
Felicitation of the best poster awards

Closing Ceremony



Glimpses of Biosimilars 2016













Media Partners @ Asian Biosimilars 2017

BENTHAM SCIENCE

Bio-Equip www.bio-equip.cn

BioPharma Asia
The Journal for Asia's Pharmaceutical and Biopharmaceutical Industry

Clinical Biometrics SOLUTIONS LIMITED

eindiabusiness.com

HAPTIC

BIO NANONET

AntibodyChain Transparency in Research!

EIN PRESSWIRE

Farmavita.R+ Regulatorry affairs network

allied academies

NEW YORK PRIVATE EQUITY FORUMS

AJP ANDREW JOHN PUBLISHING INC.

Pharmaceutical-Tech.com

PHARMA FOCUS ASIA

THE PHARMA TIMES.in www.thepharmatimes.in

TRADE SHOW Alerts Premier Trade Fair Resource

ManuscriptEdit by Reseapro

Plan your Trip to Beijing

7 UNESCO World Heritage Sites


Forbidden City



Grand Canal



Great Wall



Ming Tombs



Summer Palace




Temple of Heaven



Zhoukoudian



Forbidden City



About Beijing

Beijing (formerly Romanized as Peking) is the capital of the People's Republic of China and the world's third most populous city proper. It is also one of the world's most populous capital cities. Beijing is the second largest Chinese city by urban population after Shanghai and is the nation's political, cultural, and educational center. It is home to the headquarters of most of China's largest state-owned companies, and is a major hub for the national highway, expressway, railway, and high-speed rail networks. The Beijing Capital International Airport is the second busiest in the world by passenger traffic. The city's subway network is among the longest and busiest in the world. The city is renowned for its opulent palaces, temples, parks, gardens, tombs, walls and gates, and its art treasures and universities have made it a center of culture and art in China.

Beijing has seven UNESCO World Heritage Sites – the Forbidden City, Temple of Heaven, Summer Palace, Ming Tombs, Zhoukoudian, as well as parts of the Great Wall and the Grand Canal. Beijing hosted the 2008 Summer Olympics and was chosen to host the 2022 Winter Olympics, which will make it the first city to ever host both events.

Beijing's primary airport is the Beijing Capital International Airport (IATA: PEK) about 20 kilometers (12 mi) northeast of the city center. The airport is the second busiest airport in the world after Hartsfield-Jackson Atlanta International Airport. After renovations for the 2008 Olympics, the airport now boasts three terminals, with Terminal 3 being one of the largest in the world. Most domestic and nearly all international flights arrive at and depart from Capital Airport. It is the main hub for Air China and a hub for China Southern and Hainan Airlines. The airport links Beijing with almost every other Chinese city with regular air passenger service.

Contact Details

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific

Submit your abstract online at:

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific/abstract-submission.php

Register online:

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific/registration.php

